English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of this study was to explore the ability of 18 F-fluoroestradiol ( 18 F-FES) PET/CT imaging to predict pathologic response to neoadjuvant therapy in postmenopausal women with estrogen receptor (ER)-rich breast cancer. Methods: This was a prospective, single-center study conducted as a substudy of the neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer (NEOCENT) trial. Patients with ER-rich breast cancer were randomized to neoadjuvant chemotherapy (NC) or neoadjuvant endocrine therapy (NET). The baseline SUV max of 18 F-FES PET/CT was measured. The pathologic response was assessed by the Miller-Payne system as nonresponse (grades 1 and 2) and response (grades 3-5). Results: Twenty-six patients were enrolled, with pathologic response achieved in 25 (NC, 12; NET, 13). Two patients achieved pathologic complete response after NC, but the remaining 23 patients had residual disease after NC or NET. Eight of 12 patients responded to NC, and 4 of 13 to NET; the difference was marginally significant ( P = 0.07). In the NC group, the 2 patients with 18 F-FES-negative tumors and none of the 10 patients with 18 F-FES-avid tumors achieved pathologic complete response ( P = 0.02). No difference in the SUV max between responders and nonresponders was observed in either group. However, 5 of 7 NC patients with a baseline SUV max of less than 7.3 achieved pathologic response, whereas none of the 5 NET patients with an SUV max of less than 7.3 were responders ( P = 0.03). The SUV max values of the NC group were negatively correlated with percentage reduction of tumor cellularity ( r = -0.63, P = 0.03), whereas those of the NET group showed positive correlation ( r = 0.62, P = 0.02). During the median follow-up of 74 mo (range, 44-85 mo), recurrence occurred in only 4 NET patients. In patients with an SUV max of less than 7.3, recurrence occurred in none of the 8 NC patients and 2 of the 5 NET patients ( P = 0.13). Conclusion: Postmenopausal women who are ER-positive, but 18 F-FES-negative, may benefit from NC rather than NET. 18 F-FES PET/CT has the potential to predict response to neoadjuvant therapy in postmenopausal women with ER-rich breast cancer.

the journal of nuclear medicine

A Randomized Feasibility Study of <sup>18</sup>F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor–Rich Postmenopausal Breast Cancer

A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor–Rich Postmenopausal Breast Cancer

A Randomized Feasibility Study of ¹⁸F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor–Rich Postmenopausal Breast Cancer